Ionis Pharmaceuticals, Inc.

IONSintermediary

Ionis Pharmaceuticals is the leader in antisense technology, an approach that uses short strands of modified DNA to silence disease-causing genes at the RNA level. With Spinraza transforming SMA treatment and a rich pipeline of next-generation LICA platform drugs, Ionis is transitioning from a royalty-dependent model to a fully integrated rare disease company.

⇄ Compare

產品與營收

產品營收佔比

營收結構 ($1.8B)

靜態數據（加載即時財務…）

Royalties (Spinraza) (30%)

Product Revenue (Wainua) (25%)

Collaboration & Licensing (35%)

R&D Services (10%)

業務部門構成與主要客戶

產品詳情

Spinraza (Nusinersen)35%

Antisense therapy for spinal muscular atrophy, partnered with Biogen

Wainua (Eplontersen)35%

Next-gen LICA antisense for hereditary ATTR polyneuropathy

Pipeline Medicines30%

Olezarsen (cardiovascular), donidalorsen (HAE), and CNS programs

供應鏈關係

競爭對手

Alnylam Pharmaceuticals, Inc.

ATTR treatments (antisense vs RNAi)

影響: Direct therapeutic competitor

合作夥伴

Pfizer Inc.

Obesity antisense collaboration

影響: Major pharma partnership

Eli Lilly and Company

Neurological disease pipeline collaboration

影響: Strategic R&D partner

宏觀與市場背景

제약 / 바이오行業新聞

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化劑

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

點擊「取得 AI 分析」以獲得 Ionis Pharmaceuticals, Inc. 的 AI 供應鏈分析。

企業資訊

總部

Carlsbad, California, USA

成立時間

1989

員工人數

2,600+

官網

ionispharma.com

行業概況 — 제약 / 바이오

行業新聞